# Sanofi’s lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP.

*biotech · news · 2026-04-07 · The Manila Times*

## Key points

- Lunsekimig met primary and key secondary endpoints in phase 2 asthma and CRSwNP studies.
- AIRCULES study showed lunsekimig reduced asthma exacerbations and improved lung function regardless of biomarker status.
- DUET study confirmed lunsekimig improved nasal polyp score and nasal congestion in CRSwNP patients.
- VELVET study found lunsekimig did not meet its primary endpoint in atopic dermatitis.
- Lunsekimig was generally well tolerated, with adverse event rates similar to placebo across studies.

**Companies:** Sanofi
**Countries:** France, United States, Argentina, Belgium, Bulgaria, Poland, Czechia, Japan, China, India, Israel, Mexico, South Africa, South Korea, Turkey, UK

[Read the full story on The Manila Times](https://www.manilatimes.net/2026/04/07/tmt-newswire/globenewswire/press-release-sanofis-lunsekimig-met-primary-and-key-secondary-endpoints-in-phase-2-respiratory-studies-in-asthma-and-crswnp/2315110)

---

Canonical: https://newsio.io/n/7e25954c-c016-4a04-9f7b-c2267cd622ed/sanofis-lunsekimig-met-primary-and-key-secondary-endpoints-in-phase-2-respirator
Summarized by Newsio from The Manila Times. https://newsio.io/how-it-works